@article {Vinckenbosch17, author = {F Vinckenbosch and J Asin and N De Vries and P E Vonk and G J Lammers and S Overeem and H Janssen and G Wang and D Chen and L Carter and K Zhou and A Vermeeren and J G Ramaekers}, title = {Effects of solriamfetol on real-world driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea}, volume = {7}, number = {suppl 7}, elocation-id = {17}, year = {2021}, doi = {10.1183/23120541.sleepandbreathing-2021.17}, publisher = {European Respiratory Society}, abstract = {Background: Excessive daytime sleepiness (EDS) in people with obstructive sleep apnoea (OSA) is associated with increased driving accident risk. Solriamfetol [Sunosi{\texttrademark}] is a dopamine/norepinephrine reuptake inhibitor approved in the EU and US to treat EDS in adults with OSA (37.5{\textendash}150mg/d).Aim: Evaluate solriamfetol{\textquoteright}s effects on on-road driving performance in adults with EDS associated with OSA.Methods: In a randomised, double-blind, crossover study (NCT02806895/EudraCT 2015-003930-28), an on-road driving test was conducted at 2h and 6h postdose after 7d of treatment with solriamfetol (150mg/d{\texttimes}3d, then 300mg/d{\texttimes}4d) or placebo. Primary endpoint: standard deviation of lateral position (SDLP), a measure of weaving, at 2h postdose.Results: Baseline characteristics (N=34): 88\% male; mean age, 52y; mean Epworth Sleepiness Scale, 14.4; Maintenance of Wakefulness Test, 14.3 min. At 2h and 6h, mean SDLP was significantly lower with solriamfetol vs placebo (Fig.). At 2h, 1 participant on solriamfetol and 4 on placebo had incomplete driving tests; at 6h, 3 and 7 participants, respectively, had incomplete driving tests. Common adverse events with solriamfetol: headache, nausea, insomnia, dizziness, and agitation.Conclusion: Solriamfetol (300mg/d) improved SDLP, an important measure of driving performance, at 2h and 6h postdose in participants with EDS associated with OSA.FootnotesCite this article as ERJ Open Research 2021; 7: Suppl. 7, 17.This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, URL = {https://openres.ersjournals.com/content/7/suppl_7/17}, eprint = {https://openres.ersjournals.com/content}, journal = {ERJ Open Research} }